MedTrace Logo

Antibiotic Resistance of Helicobacter Pylori in Nanjing: A Cross-Sectional Study

NCT07455448 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 7227

Last updated 2026-04-09

No results posted yet for this study

Summary

This study aims to provide an updated analysis of the resistance patterns of H. pylori in the Nanjing region, with a focus on characterizing the current status of phenotypic and genotypic resistance to these six antimicrobial agents. The findings are expected to offer a scientific basis for the rapid diagnosis and personalized treatment of H. pylori infection.

Conditions

  • HELICOBACTER PYLORI INFECTIONS

Interventions

DIAGNOSTIC_TEST

Antimicrobial susceptibility testing

This study employed a retrospective, single-center, cross-sectional epidemiological design. Medical records of outpatients who underwent H. pylori culture and genetic testing at the gastroenterology clinic between 2018 and 2025 were retrospectively reviewed. The study aimed to characterize the resistance patterns of H. pylori in the Nanjing region, with a focus on elucidating the current status of phenotypic and genotypic resistance to amoxicillin, clarithromycin, metronidazole, levofloxacin, tetracycline, and furazolidone. The findings are intended to assist clinicians in the rapid diagnosis and individualized treatment of H. pylori infection.

Sponsors & Collaborators

  • Nanjing First Hospital, Nanjing Medical University

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-01
Primary Completion
2026-03-25
Completion
2026-03-25

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07455448 on ClinicalTrials.gov